Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
NL0015436031
Tue, 16.04.2024
CureVac
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
Agreement creates strong synergies between CureVac’s unique end-to-end mRNA capabilities and MD Anderson’s translational and clinical research expertise
Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematologic [ … ]
Fri, 05.01.2024
CureVac
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
Head-to-head comparison with licensed bivalent mRNA-based comparator vaccine confirms competitive immune responses at lower doses and favorable tolerability profile
M [ … ]
Tue, 19.12.2023
CureVac
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation
with BioNTech SE
Validity of CureVac patent EP 1 857 122 B1 denied by German Federal Patent Court after nullity action filed by BioNTech SE
Decision does not affect ongoing litigation in Germany regarding seven other intellectual property rights, covering stron [ … ]
Tue, 14.11.2023
CureVac
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
Enrollment completed for Phase 2 COVID-19 study with mono- and bivalent vaccine candidates; study on track for data read-out in early 2024
First participant dosed in seasonal flu Phase 2 study with potentially differentiated mul [ … ]
Wed, 01.11.2023
CureVac
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs
in Collaboration with GSK
COVID-19 Phase 2 clinical trial fully enrolled
Study compares mono- and bivalent vaccine candidates against licensed comparator COVID-19 vaccine
First participant dosed in seasonal flu Phase 2 part of combined Phase [ … ]
Thu, 28.09.2023
CureVac
CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany
Regional Court Düsseldorf postpones infringement ruling on four intellectual property rights in lawsuit filed by CureVac against BioNTech
Ruling on infringement to be provided latest once the validity of the intellectual property rights in suit has b [ … ]
Tue, 12.09.2023
CureVac
CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
Phase 1 part of combined Phase 1/2 study assessed comprehensive series of flu vaccine candidates, featuring up to eight separate mRNA constructs per candidate
Best-performing candidate providing [ … ]
Thu, 17.08.2023
CureVac
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
Initiated Phase 2 study in COVID-19 with monovalent and bivalent, modified mRNA vaccine candidates; continued execution on infectious disease development program in collaboration with GSK
Initiated Phase 1 study of cancer vaccine candida [ … ]
Tue, 01.08.2023
CureVac
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
Phase 2 study initiated at clinical sites in Australia with monovalent and bivalent mRNA COVID-19 vaccine candidates
Vaccine candidates developed in collaboration with GSK within COVID-19 vaccine develo [ … ]
Tue, 01.08.2023
CureVac
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
Phase 2 study initiated at clinical sites in Australia with monovalent and bivalent mRNA COVID-19 vaccine candidates
Vaccine candidates developed in collaboration with GSK within COVID-19 vaccine develo [ … ]